298 related articles for article (PubMed ID: 25387618)
1. Diagnostic and prognostic significance of suPAR in traumatic brain injury.
Yu L; Wu X; Wang H; Long D; Yang J; Zhang Y
Neurol India; 2014; 62(5):498-502. PubMed ID: 25387618
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
[TBL] [Abstract][Full Text] [Related]
4. [Change in plasma microparticle procoagulant activity after traumatic brain injury].
Huang M; Cai HB; Hu YY; Dong XQ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2265-8. PubMed ID: 20095339
[TBL] [Abstract][Full Text] [Related]
5. Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury.
Gatson JW; Barillas J; Hynan LS; Diaz-Arrastia R; Wolf SE; Minei JP
J Neurosurg; 2014 Nov; 121(5):1232-8. PubMed ID: 25192482
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
[TBL] [Abstract][Full Text] [Related]
7. Copeptin is associated with mortality in patients with traumatic brain injury.
Dong XQ; Huang M; Yang SB; Yu WH; Zhang ZY
J Trauma; 2011 Nov; 71(5):1194-8. PubMed ID: 21502880
[TBL] [Abstract][Full Text] [Related]
8. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
[TBL] [Abstract][Full Text] [Related]
9. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
[TBL] [Abstract][Full Text] [Related]
10. Tau proteins in serum predict outcome after severe traumatic brain injury.
Liliang PC; Liang CL; Weng HC; Lu K; Wang KW; Chen HJ; Chuang JH
J Surg Res; 2010 May; 160(2):302-7. PubMed ID: 19345376
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection.
Berres ML; Schlosser B; Berg T; Trautwein C; Wasmuth HE
J Clin Gastroenterol; 2012 Apr; 46(4):334-8. PubMed ID: 21934527
[TBL] [Abstract][Full Text] [Related]
12. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
Donadello K; Scolletta S; Taccone FS; Covajes C; Santonocito C; Cortes DO; Grazulyte D; Gottin L; Vincent JL
J Crit Care; 2014 Feb; 29(1):144-9. PubMed ID: 24120089
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 is an independent biomarker of severe traumatic brain injury prognosis.
Schneider Soares FM; Menezes de Souza N; Libório Schwarzbold M; Paim Diaz A; Costa Nunes J; Hohl A; Nunes Abreu da Silva P; Vieira J; Lisboa de Souza R; Moré Bertotti M; Schoder Prediger RD; Neves Linhares M; Bafica A; Walz R
Neuroimmunomodulation; 2012; 19(6):377-85. PubMed ID: 23075771
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
17. [Can mannose-binding lectin and plasma level of soluble urokinase receptor be used in diagnosis and treatment monitorization of brucellosis patients?].
Karsen H; Cesur S; Karaağaç L; Binici I; Fidan Y; Oğüş E; Demiröz AP
Mikrobiyol Bul; 2012 Jul; 46(3):519-21. PubMed ID: 22951667
[TBL] [Abstract][Full Text] [Related]
18. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.
Geboers DG; de Beer FM; Tuip-de Boer AM; van der Poll T; Horn J; Cremer OL; Bonten MJ; Ong DS; Schultz MJ; Bos LD
Intensive Care Med; 2015 Jul; 41(7):1281-90. PubMed ID: 26100127
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
